Microbiome Therapeutics Market Set to Witness an Uptick during 2019 to 2025
The microbiome therapeutics market is expected to reach USD 433.5 million by 2025, based on a new study by Grand View Research, Inc. Increasing funding initiatives and government programs to support this research are high impact rendering drivers anticipated to foster market growth.
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.
The launch of Human Microbiome Project by NHS in Europe and the Microbiome Initiative by the U.S. government are some of the crucial government initiatives pertaining to market growth. The U.S. government has announced to have invested over USD 121 million in the Microbiome Initiative with additional USD 100 million from the Bill and Melinda Gates Foundation.
Presence of strong drug pipeline can also be attributed to the highly lucrative growth. Key players are entering into collaborative agreements with venture capital firms and research institutes for enhancing therapeutics pipeline through development of efficient and safe drugs. Some of the companies that recently formed collaborative agreements are Seventure Partners & ENTEROME Bioscience; Vedanta Biosciences & Johnson & Johnson Pvt. Ltd.; and Seventure Partners & Eligo Bioscience.
To Request Sample Copy of this report, click the link:
https://www.grandviewresearch.com/industry-analysis/microbiome-therapeutics-market/request/rs1
Further Key Findings from the Study Suggest:
Gut microbiome has been known to be associated with the good health of a person. Researchers have reported that alteration in a number of microorganisms such as firmicute, bacteroidetes, and actinobacteria leads to the development of gastrointestinal disorders, diabetes, arthritis, and other neurological disorders. Heavy and long-term use of antibiotics, unhealthy lifestyle, and increasing age are some of the factors reducing the number of beneficial microorganisms in the human body.
Low level of beneficial microbiota helps the growth of fatal infectious diseases and organisms, such as Clostridium difficile (C. difficile) and ulcerative colitis. C. difficile has been reported to affect over half a million people in a single year and has a high recurrence rate. People on antibiotic treatment are 7 to 10 times more likely to get affected by C. difficile infection during the treatment and the months following it.
Increasing collaboration between pharmaceutical companies for development of novel drugs is also a high impact rendering factor for growth. For instance, Seres Therapeutics, U.S., and Nestlé Health Science have entered into a collaborative agreement for development and commercialization of extensive product pipeline for ulcerative colitis and C. difficile infection.
Have any Query? Ask our Experts:
https://www.grandviewresearch.com/inquiry/3401/ibb
Grand View Research has segmented the microbiome therapeutics market on the basis of type and application:
Type Outlook (Market Revenue in USD Million, 2014 - 2025)
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.
The launch of Human Microbiome Project by NHS in Europe and the Microbiome Initiative by the U.S. government are some of the crucial government initiatives pertaining to market growth. The U.S. government has announced to have invested over USD 121 million in the Microbiome Initiative with additional USD 100 million from the Bill and Melinda Gates Foundation.
Presence of strong drug pipeline can also be attributed to the highly lucrative growth. Key players are entering into collaborative agreements with venture capital firms and research institutes for enhancing therapeutics pipeline through development of efficient and safe drugs. Some of the companies that recently formed collaborative agreements are Seventure Partners & ENTEROME Bioscience; Vedanta Biosciences & Johnson & Johnson Pvt. Ltd.; and Seventure Partners & Eligo Bioscience.
To Request Sample Copy of this report, click the link:
https://www.grandviewresearch.com/industry-analysis/microbiome-therapeutics-market/request/rs1
Further Key Findings from the Study Suggest:
- Fecal Microbial Transplant (FMT) held the largest market share in 2015 owing to easier availability and introduction of FMT capsules by Open Biome
- Introduction of RBX2660, a phase 3 molecule, during the end of 2018 will result in substantial increase in revenue of FMT
- No commercial microbiome drugs are currently available with FMT being the only therapy for treatment. Drugs are estimated to hit the market by fourth quarter of 2017.
- It is estimated that the drugs segment would witness the fastest growth owing to the presence of blockbuster drugs, such as, NM504, SER-109, RP-G28, and SGM-1019, in the pipeline
- difficiledominated the application segment in 2015 with Crohn’s disease leading the market CAGR over the forecast period
- North America held the largest share in 2015, owing to presence of major companies & established healthcare infrastructure and high amount of research activities
- Asia Pacific is anticipated to witness significant growth with increasing acceptance of FMT in developing countries, such as India and China
- Some of the key companies are MicroBiome Therapeutics, LLC; Seres Therapeutics; ENTEROME Bioscience; MaaT Pharma; Rebiotix, Inc.; Ritter Pharmaceuticals; Second Genome, Inc.; and OpenBiome
- High investment on research and development of new drugs and investigation of available drugs for more untapped applications are the main strategies undertaken by the key players
Gut microbiome has been known to be associated with the good health of a person. Researchers have reported that alteration in a number of microorganisms such as firmicute, bacteroidetes, and actinobacteria leads to the development of gastrointestinal disorders, diabetes, arthritis, and other neurological disorders. Heavy and long-term use of antibiotics, unhealthy lifestyle, and increasing age are some of the factors reducing the number of beneficial microorganisms in the human body.
Low level of beneficial microbiota helps the growth of fatal infectious diseases and organisms, such as Clostridium difficile (C. difficile) and ulcerative colitis. C. difficile has been reported to affect over half a million people in a single year and has a high recurrence rate. People on antibiotic treatment are 7 to 10 times more likely to get affected by C. difficile infection during the treatment and the months following it.
Increasing collaboration between pharmaceutical companies for development of novel drugs is also a high impact rendering factor for growth. For instance, Seres Therapeutics, U.S., and Nestlé Health Science have entered into a collaborative agreement for development and commercialization of extensive product pipeline for ulcerative colitis and C. difficile infection.
Have any Query? Ask our Experts:
https://www.grandviewresearch.com/inquiry/3401/ibb
Grand View Research has segmented the microbiome therapeutics market on the basis of type and application:
Type Outlook (Market Revenue in USD Million, 2014 - 2025)
- FMT
- Microbiome Drugs
- difficile
- Crohn’s disease
- Inflammatory Bowel Disease
- Diabetes
- Others
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
Comments
Post a Comment